Zelboraf is an oral, small molecule, kinase inhibitor indicated for the treatment of patients with inoperable or metastatic melanoma with BRAF V600 mutations.
Zelboraf is not recommended for use in melanoma patients with wild-type BRAF.
Approved in the US, EU and Switzerland
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals and patients are asked to report any suspected adverse reactions. See our information for details on how to report.